Pyrrolo[2,3-D]pyrimidine compounds
AssigneePfizer Inc.
InventorsTodd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof
Life of this patent
Estimating the term…
Abstract
A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.
Claims18
A method for treating atopic dermatitis comprising administering a therapeutically effective amount of 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile or a pharmaceutically acceptable salt thereof to a mammal in need thereof.
A method for treating ulcerative colitis comprising administering a therapeutically effective amount of 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile or a pharmaceutically acceptable salt thereof to a mammal in need thereof.
A method for treating Crohn's disease comprising administering a therapeutically effective amount of 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile or a pharmaceutically acceptable salt thereof to a mammal in need thereof.
Dependencies are inferred from the claim text.